Radiopharmaceutical management of 90Y/111 in labeled antibodies: Shielding and quantification during preparation and administration

Annals of Nuclear Medicine

Volumn 20, Issue 8, 2006, Pages 575-581

  Van Hemert, Formijn J ^a   Sloof, Gerrit W ^a   Schimmel, Kirsten J M ^a   Vervenne, Walter L ^a   Van Eck Smit, Berthe L F ^a   Busemann Sokole, Ellinor ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Quench correction; Radiation protection; Radioimmunotherapy; Radionuclide calibration; Radiopharmaceutical

Indexed keywords

ANTIBODY; RADIOPHARMACEUTICAL AGENT; YTTRIUM 90; DIAGNOSTIC AGENT; INDIUM; YTTRIUM;

ARTICLE; CALIBRATION; DRUG EFFICACY; LIQUID SCINTILLATION COUNTING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOIMMUNOTHERAPY; CHEMISTRY; EQUIPMENT DESIGN; HUMAN; INSTRUMENTATION; METABOLISM; METHODOLOGY; RADIOIMMUNOASSAY; SCINTISCANNING; TIME;

ANTIBODIES; CALIBRATION; EQUIPMENT DESIGN; HUMANS; INDIUM RADIOISOTOPES; RADIOIMMUNODETECTION; RADIOIMMUNOTHERAPY; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; TIME FACTORS; YTTRIUM RADIOISOTOPES;

EID: 33751416214     PISSN: 09147187     EISSN: 09147187     Source Type: Journal    
DOI: 10.1007/BF03026825     Document Type: Article

References (19)

1. 90Y-labeled CD20 monoclonal antibody. Clin Cancer Res 1999; 5: 3281s-3286s.
2. 90yttrium ibritumomab tiuxetan; IDEC-Y2B8) radioimmunotherapy for treatment of relapsed or refractory CD20 positive B-cell non-Hodgkin's lymphoma. J Clin Oncology 1999; 17: 3793-3803.
3. 131I-labeled murine and humanized anti-carcinoembryonic antigen monoclonal antibodies. Gyneco Oncol 1997; 76: 259-271.
4. 131I-MN-14(F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma. Cancer 1999; 85: 1828-1842.
5. Sharkey RM, Goldenberg DM, Murthy S, Pinsky H, Vagg R, Pawlyk D, et al. Clinical evaluation of tumor targeting with a high-affinity, anticarcinoembryonic-antigen-specific, murine monoclonal antibody, MN-14. Cancer 1993; 71: 2082-2096.
6. 90Y Ibritumomab Tiuxetan (Zevalin). Semin Nucl Med 2004; XXXIV, 1 (Suppl): 14-19.
7. 90Y Ibritumomab Tiuxetan (Zevalin). Semin Nucl Med 2004; XXXIV, 1 (Suppl): 10-13.
8. 90Y Ibritumomab Tiuxetan (Zevalin). Semin Nucl Med 2004; XXXIV, 1 (Suppl): 4-9.
9. 90Y Ibritumomab Tiuxetan (Zevalin). Semin Nucl Med 2004; XXXIV, 1 (Suppl): 20-23.
10. 90Y. Appl Radiat Isot 2004; 60: 741-749.
11. Zanzonico PB, Binkert BL, Goldsmith SJ. Bremsstrahlung radiation exposure from pure beta-ray emitters. J Nucl Med 1999; 40: 1024-1028.
12. Coursey BM, Calhoun JM, Cessna JT. Radioassays of yttrium-90 used in nuclear medicine. Nucl Med Biol 1993; 20: 693-699.
13. Coursey BM, Collé R, Zimmerman BE, Cessna JT, Golas DB. National radioactivity standards for β-emitting radionuclides used in intravascular brachytherapy. Int J Radiation Oncology Biol Phys 1998; 41: 207-216.
14. 90Y using commercial radionuclide calibrators. Appl Radiat Isot 2004; 60: 511-517.
15. 90Y Zevalin. Health Phys 2003; 85: S31-S35.
16. Parker RP, Elrick RH. The assay of beta-emitting radioisotopes using Cerenkov counting. Int J Appl Radiat Isot 1996; 17: 361-362.
17. Francois B. Detection of hard beta-emitting radionuclides in aqueous solutions using Cerenkov radiation: a review article. Int J Nucl Med Biol 1973; 1: 1-14.
18. L'Annunziata MF, Passo CJ. Cerenkov counting of yttrium-90 in the dry state; correlations with phosphorus-32 Cerenkov counting data. Appl Radiat Isot 2002; 56: 907-916.
19. 99mTc-mertiatide (Mag-3). Ann Nucl Med 2005; 19: 345-349.